|
Actinium Pharmaceuticals, Inc. (ATNM): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Actinium Pharmaceuticals, Inc. (ATNM) Bundle
In the cutting-edge world of precision oncology, Actinium Pharmaceuticals, Inc. (ATNM) emerges as a pioneering force, revolutionizing cancer treatment through its innovative radioimmunotherapeutic technologies. By harnessing the power of targeted alpha-particle therapy and developing breakthrough treatments like Iomab-B, this New York-based biotech company is transforming how we approach challenging hematologic malignancies, particularly for elderly patients with relapsed/refractory acute myeloid leukemia (AML). Dive into the strategic marketing landscape that positions Actinium at the forefront of personalized cancer care, exploring how their unique product, strategic placement, targeted promotion, and sophisticated pricing model are reshaping the future of oncological treatments.
Actinium Pharmaceuticals, Inc. (ATNM) - Marketing Mix: Product
Targeted Radiotherapeutics Development
Actinium Pharmaceuticals specializes in developing precision cancer treatments using radioactive isotopes.
| Product Category | Details |
|---|---|
| Primary Technology | Alpha-particle radiotherapeutic technologies |
| Key Isotopes | Actinium-225 and Bismuth-213 |
| Primary Target | Cancer treatment |
Lead Product: Iomab-B
Iomab-B is designed for elderly patients with relapsed/refractory Acute Myeloid Leukemia (AML).
- Target patient population: Patients aged 55 and older
- Indication: Relapsed/refractory AML
- Clinical stage: Phase 3 clinical trials
Product Pipeline
| Product | Target Indication | Development Stage |
|---|---|---|
| Iomab-B | AML Patient Bridge to Bone Marrow Transplant | Phase 3 |
| Actimab-A | AML First-Line Treatment | Phase 1b/2 |
| Actimab-M | Myelodysplastic Syndrome | Preclinical |
Technological Specialization
Focuses on radioimmunotherapeutic treatments utilizing alpha-particle emission technologies.
- Precision targeting of cancer cells
- Minimal damage to surrounding healthy tissue
- Potential for improved patient outcomes
Actinium Pharmaceuticals, Inc. (ATNM) - Marketing Mix: Place
Headquarters and Geographic Presence
Actinium Pharmaceuticals, Inc. is headquartered at 275 Madison Avenue, 7th Floor, New York City, NY 10016, United States.
Primary Market Reach
North American Oncology Market Focus
| Geographic Region | Market Concentration | Primary Target Facilities |
|---|---|---|
| United States | 90% of clinical operations | Comprehensive Cancer Centers |
| Canada | 10% of clinical operations | Regional Cancer Treatment Centers |
Clinical Trial Distribution
Research Institutions Engaged in Clinical Trials:
- Memorial Sloan Kettering Cancer Center
- MD Anderson Cancer Center
- Dana-Farber Cancer Institute
- University of Pennsylvania
- City of Hope National Medical Center
Distribution Channels
| Channel Type | Percentage of Distribution | Facility Types |
|---|---|---|
| Direct Hospital Sales | 65% | Specialized Cancer Treatment Centers |
| Oncology Research Institutions | 25% | Academic Medical Centers |
| Specialized Pharmaceutical Distributors | 10% | Oncology-focused Distributors |
Clinical Trial Geographic Spread
Active Clinical Trial Locations
- Northeast United States: 40% of trials
- West Coast United States: 30% of trials
- Midwest United States: 20% of trials
- Canada: 10% of trials
Actinium Pharmaceuticals, Inc. (ATNM) - Marketing Mix: Promotion
Conference Presentations
Actinium Pharmaceuticals presents research at key oncology conferences, including:
| Conference | Year | Presentations |
|---|---|---|
| American Society of Hematology (ASH) | 2023 | 4 scientific presentations |
| American Association for Cancer Research (AACR) | 2023 | 3 research abstracts |
Investor Relations and Scientific Communication
Communication channels include:
- Quarterly earnings calls
- Investor presentations
- Scientific publications in peer-reviewed journals
Medical and Scientific Marketing
Targeted marketing strategies focus on:
- Oncology specialists
- Hematology researchers
- Academic medical centers
Community Outreach
| Outreach Channel | Engagement Metrics |
|---|---|
| Scientific webinars | 12 hosted in 2023 |
| Investor conferences | 6 participated in 2023 |
Clinical Trial Communication
Press release distribution metrics:
- Total press releases in 2023: 15
- Clinical trial progress updates: 8 releases
- Average press release reach: 50,000 viewers
Actinium Pharmaceuticals, Inc. (ATNM) - Marketing Mix: Price
Precision Cancer Therapy Pricing Dynamics
Actinium Pharmaceuticals, Inc. operates in the high-value precision cancer therapy market with specialized radioimmunotherapeutic solutions.
| Financial Metric | 2023 Value |
|---|---|
| Research & Development Expenses | $41.3 million |
| Net Loss | $54.2 million |
| Cash and Cash Equivalents | $89.7 million |
Pricing Strategy Components
Key Pricing Strategy Elements:
- Advanced targeted therapeutic treatment pricing model
- Premium pricing approach for innovative radioimmunotherapies
- Reimbursement strategies through healthcare insurance channels
Reimbursement Considerations
Pricing influenced by clinical trial outcomes and potential regulatory approvals for breakthrough cancer treatments.
| Clinical Trial Stage | Potential Pricing Impact |
|---|---|
| Phase I/II Trials | Preliminary pricing assessment |
| Phase III Trials | Definitive pricing strategy development |
| FDA Approval Potential | Full market pricing implementation |
Market Positioning
Pricing strategy aligned with high-value precision oncology market segment, targeting specialized therapeutic interventions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.